Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.
Over the last decade the field of medicine has dramatically changed with the introduction of biological therapies, among which monoclonal antibodies play a pivotal role in the management of many diseases. Rozrolimupab is the first of a new class of recombinant human monoclonal antibody mixtures, consisting of 25 genetically unique IgG1 antibodies, targeted against the RhD erythrocyte antigen. It is currently being investigated for its use in the treatment of primary immune thrombocytopenia. This article outlines the impetus for the development of rozrolimupab in the treatment of ITP. In addition, the literature regarding the development of rozrolimupab and the recent clinical trials involving this agent are also reviewed. Although rozrolimupab is only in the very early phases of clinical development we believe that this agent represents a very interesting agent not only for its potential benefits in the management of ITP but potentially for the prevention of haemolytic disease of the foetus and newborn.